Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

PHASE4CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

June 12, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

January 30, 2020

Conditions
Pulmonary Embolism and Thrombosis
Interventions
DEVICE

Ekosonic® Endovascular Device ultrasonic infusion catheter

r-tPA will be administered via EKOS.

BIOLOGICAL

Recombinant tissue plasminogen activator

Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.

Trial Locations (21)

16507

UPMC Hamot, Erie

19096

Lankenau Medical Center, Wynnewood

30309

Piedmont Hospital, Atlanta

30901

University Hospital, Augusta

32308

Tallahassee Memorial Hospital, Tallahassee

33613

Florida Hospital Tampa, Tampa

37232

Vanderbilt University Medical Center, Nashville

40202

Jewish Hospital, Louisville

43213

Mount Carmel Health System, Columbus

46260

St. Vincent Medical Group, Indianapolis

48201

Detroit Medical Center, Detroit

70006

East Jefferson General Hospital, Metairie

77469

Houston Methodist Sugarland Hospital, Richmond

90211

Cedars Sinai, Beverly Hills

99204

Providence Sacred Heart Medical Center, Spokane

Unknown

Inova Alexandria Hospital, Alexandria

EX2 5DW

Royal Devon & Exeter Hospital, Exeter

ME7 5NY

Medway Maritime Hospital, Gillingham

NW3 2QG

Royal Free Hospital, London

SE1 7EH

St. Thomas Hospital, London

DD1 9SY

Ninewells Hospital, Dundee

Sponsors
All Listed Sponsors
collaborator

EKOS Corporation

INDUSTRY

lead

Boston Scientific Corporation

INDUSTRY